496.70
-2.26%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Coloplast A/S
Its shares trade on Nasdaq Copenhagen under the ticker COLO B.CO. It has been listed since 1 January 1983. In the fiscal year to 30 September 2025, it reported revenue of DKK 27.87bn and net income of DKK 3.64bn. At that date it held total assets of DKK 48.37bn and shareholders' equity of DKK 16.12bn.
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Jan 1983
- Employees
- 12,000
- Website
- coloplast.dk ↗
Leadership
Pay as last reported
- Ms. Jette Nygaard-AndersenInterim Independent Chairman of the BoardDKK 600,000
- Mr. Lars RasmussenInterim President, Interim Chief Executive Officer, Member of the Executive Leadership Team, DirectorDKK 1.8m
- Mr. Niels Louis-HansenDeputy Chairman of the BoardDKK 938,000
- Mr. Anders Lonning-SkovgaardChief Financial Officer, Executive Vice President, Member of the Executive Leadership TeamDKK 11.3m
- Ms. Dorthe RonnauExecutive Vice President - People and Culture, Member of the Executive Leadership Team
- Mr. Thomas JohnsExecutive Vice President - Interventional Urology, Member of the Executive Leadership Team
- Mr. Allan RasmussenExecutive Vice President - Global Operations, Member of the Executive Leadership Team, since 2014DKK 9.9m
- Mr. Fertram SigurjonssonExecutive Vice President - Wound & Tissue Repair, Member of the Executive Leadership Team
- Ms. Caroline Vagner RosenstandExecutive Vice President - Chronic Care Commercial, Member of the Executive Leadership Team
- Mr. Thomas BarfodDirector, Employee RepresentativeDKK 450,000
- Mr. Nikolaj GundersenDirector, Employee RepresentativeDKK 450,000
- Mr. Roland PedersenDirector, Employee RepresentativeDKK 450,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 78
- Social
- 81
- Governance
- 58
- Direct emissions (scope 1)
- 21,282 t
- Energy emissions (scope 2)
- 32,170 t
- Value chain emissions (scope 3)
- 197,836 t
- Women in the workforce
- 62%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Coloplast A/S has several strengths that contribute to its success in the market. These strengths include a strong brand reputation, a wide range of innovative products, and a global presence. The company has established itself as a market leader in the healthcare industry, known for its high-quality and reliable products.
- Coloplast A/S has built a strong brand reputation over the years, earning the trust and loyalty of customers worldwide. The company is recognized for its commitment to customer satisfaction and delivering effective healthcare solutions.
- Coloplast A/S consistently introduces innovative products that address the evolving needs of customers. Its extensive product portfolio includes advanced medical devices and supplies, offering various solutions for ostomy care, continence care, and wound care.
- With a global presence in over 100 countries, Coloplast A/S enjoys a widespread distribution network. This extensive reach allows the company to serve a diverse customer base and penetrate different markets, contributing to its revenue growth and market share.
Weaknesses
- Although Coloplast A/S is a robust company, it also faces certain weaknesses that need to be addressed to maintain its competitive edge in the market. These weaknesses include dependence on a limited number of suppliers, vulnerability to regulatory changes, and higher pricing compared to some competitors.
- Coloplast A/S sources its raw materials and components from a limited number of suppliers, making it susceptible to disruptions in the supply chain. Any issues or delays in the supply chain could impact the company's manufacturing capabilities and product availability.
- As a healthcare company, Coloplast A/S is subject to strict regulations governing the manufacturing, marketing, and sale of its products. Changes in regulatory requirements or non-compliance with existing regulations could pose challenges for the company and potentially impact its operations.
- In comparison to some competitors, Coloplast A/S products are relatively higher priced. This pricing strategy may limit the company's market penetration and pose challenges in price-sensitive markets where competitors offer more affordable alternatives.
Opportunities
- Coloplast A/S operates in a dynamic market that presents several opportunities for growth and expansion. These opportunities include emerging markets, increasing demand for advanced healthcare solutions, and technological advancements in the healthcare industry.
- Expanding into emerging markets can provide Coloplast A/S with new customer segments and revenue streams. These markets often have a growing population, increasing healthcare awareness, and expanding healthcare infrastructure, creating a conducive environment for the company's products.
- As the global population ages and healthcare needs continue to evolve, there is an increasing demand for advanced healthcare solutions. Coloplast A/S can capitalize on this trend by developing and offering innovative products that improve patient outcomes and quality of life.
- Technological advancements in the healthcare industry provide Coloplast A/S with opportunities to create new and improved products. By investing in research and development, the company can leverage these advancements to enhance its product offerings and maintain a competitive edge.
Threats
- Coloplast A/S faces various external threats that could impact its business operations and market position. These threats include intense competition, changing market dynamics, and economic uncertainties caused by factors such as currency fluctuations and geopolitical tensions.
- The healthcare industry is highly competitive, with numerous companies vying for market share. Coloplast A/S faces competition from both established players and emerging companies, requiring it to continually innovate and differentiate its products to maintain its market position.
- Market dynamics within the healthcare industry can rapidly change due to factors such as evolving customer preferences, shifting regulations, and advances in technology. Coloplast A/S must adapt to these changes and proactively anticipate market trends to remain competitive.
- Economic uncertainties, including currency fluctuations and geopolitical tensions, can impact Coloplast A/S's business operations and financial performance. Changes in exchange rates and instability in global markets may affect the company's revenue, profitability, and supply chain.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.